Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 80Neoplasm Metastasis 6Neoplasms 3Breast Neoplasms, Male 3Arthralgia 2Triple Negative Breast Neoplasms 1Sleep Wake Disorders 1Skin Diseases 1Prostatic Neoplasms 1Post Menopausal Women With Early Breast Cancer 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Obesity 1Metastatic Beast Cancer 1Mammary Neoplasms, Animal 1Lymphoma 1Lethal Congenital Contracture Syndrome 2 1Invasive Early Breast Cancer 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Fatigue 1Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Advanced Breast Carcinoma 1

Interventions

Megestrol Acetate 2exemestane 1Pterocarpus marsupium 1Pharmacogenomic Variants 13,5-dimethoxy-4'-hydroxystilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Hyperplasia × exemestane × Clear all
NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 13 charts
Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡